What to Know About Your Stage 1 ccRCC Diagnosis

Receiving a diagnosis of stage 1 clear cell renal cell carcinoma (ccRCC) can be a shock, but it is important to know that this is the most common and most treatable stage of kidney cancer. At this stage, the cancer is caught early, and the focus of your medical team will likely be on achieving a complete cure.

The following guide is designed to help you understand your diagnosis and prepare you for an informed conversation with your urologist or oncologist.

1. Overview of Stage 1 ccRCC

Clear cell is the most common subtype of kidney cancer, accounting for about 80% of cases. It is named for the way the cells appear under a microscope—clear, like soap bubbles.

• Defining Stage 1: The tumor is 7 centimeters or smaller (about the size of a tennis ball) and is contained entirely within the kidney. It has not spread to lymph nodes or distant organs.
• The Outlook: Stage 1 has an exceptionally high success rate. Because the tumor is localized, many patients are cured through surgery or localized treatment alone and do not require long-term medication.

2. Diagnosis and Staging of ccRCC

Most Stage 1 tumors are found "incidentally", meaning they were discovered during a scan (like a CT or ultrasound) for an unrelated reason, such as back pain or a check-up.

• Imaging: Contrast-enhanced CT scans or MRIs are used to measure the tumor precisely and confirm it hasn't crossed the kidney's boundary.
• Biopsy: While not always required if imaging is clear, a needle biopsy may be performed to confirm the "Clear Cell" type or to help decide if "Active Surveillance" is safe for you.
• Grading (Fuhrman/ISUP): Your pathologist will assign a grade from 1 to 4. Grade 1 cells look very much like healthy cells and grow slowly; Grade 4 cells look more aggressive. Knowing your grade helps your doctor predict how the tumor might behave.

3. Treatment Options for Stage 1 ccRCC

For Stage 1, the standard of care has shifted toward "nephron-sparing" treatments—meaning the goal is to save as much of your healthy kidney tissue as possible.

Surgical Intervention

• Partial Nephrectomy: This is the preferred treatment. Only the tumor and a small margin of healthy tissue are removed. This preserves kidney function, which is vital for your long-term heart and metabolic health.
• Radical Nephrectomy: If the tumor is located deep in the center of the kidney or is near major blood vessels, the entire kidney may need to be removed. Most people live a perfectly normal life with one healthy kidney.

“Minimally invasive surgery and these three-dimensional imaging modalities have allowed us to offer the majority of our patients a partial nephrectomy,” Dr. Ravi Munver, the vice chair of Urology at John Theurer Cancer Center and professor of Urology and chief of Minimally Invasive and Robotic Surgery at Hackensack University Medical Center in Hackensack, New Jersey, explained in a previous interview with CURE. “Partial nephrectomy means removing just the part of the kidney with the tumor itself and preserving the rest of the kidney so that patients can have a better quality of life and minimize their risk of needing dialysis in the future.”

Minimally Invasive Alternatives

• Ablation (Cryotherapy or Radiofrequency): For very small tumors (usually under 3-4 cm) or for patients who may not tolerate surgery well, doctors can use extreme cold or heat to "freeze" or "burn" the tumor away without traditional surgery.
• Active Surveillance: If the tumor is very small (under 3 cm) and growing slowly, your doctor may recommend regular scans every 3 to 6 months rather than immediate surgery.

4. Potential Side Effects of Stage 1 ccRCC Treatment

Treatment for Stage 1 is generally well-tolerated, but it is helpful to be aware of what to expect during recovery.

Treatment for ccRCC can be associated with distinct short- and long-term effects, depending on the approach used. Following surgery, patients may experience incision-related pain, fatigue, and temporary constipation related to pain medications; these effects are commonly managed with early ambulation after surgery and a high-fiber diet. Ablation is typically associated with minor discomfort or bruising at the needle insertion site, with a rare risk of localized bleeding, and is often performed as an outpatient procedure with a relatively quick recovery period.

Over the long term, some patients may experience a slight decrease in overall kidney function, which is routinely monitored through blood tests; management focuses on maintaining adequate hydration and avoiding high doses of nonsteroidal anti-inflammatory drugs, such as ibuprofen.

5. What to Understand About Your Stage 1 ccRCC

A stage 1 diagnosis is highly manageable. Because the cancer is localized, the primary focus is on removing the mass while protecting your overall kidney health. Once the initial treatment is complete, you will move into a "surveillance" phase, involving periodic scans to ensure you remain cancer-free.

Questions to Drive the Conversation with Your Urologist:

• "Am I a candidate for a partial nephrectomy (kidney-sparing surgery) rather than a radical one?"
• "Can this procedure be done robotically or laparoscopically to speed up my recovery?"
• "Given my age and health, is Active Surveillance an option for me right now?"
• "How will we monitor my kidney function (GFR) after the procedure?"
• "What was the Grade of my tumor, and how does that influence how often I need follow-up scans?"

Editor's note: This article is for informational purposes only and is not a substitute for professional medical advice, as your own experience will be unique. Use this article to guide discussions with your oncologist. Content was generated with AI, reviewed by a human editor, but not independently verified by a medical professional.

Reference

1. Minimally Invasive Kidney Cancer Treatments Boosts Patient Recovery, by Dr. Ravi Munver. CURE; Oct. 9, 2025. https://www.curetoday.com/view/minimally-invasive-kidney-cancer-treatments-boosts-patient-recovery

For more news on cancer updates, research and education, don’t forget to subscribe to CURE®’s newsletters here.